A rapid method for obtaining mesenchymal stem cells and platelets from bonemarrow aspirate
Academic Article
Publication Date:
2014
Short description:
A rapid method for obtaining mesenchymal stem cells and platelets from bonemarrow aspirate / Dozza, B., Gobbi, G., Lucarelli, E., Pierini, M., Bella, C.D., Frisoni, T., Tazzari, P.L., Ricci, F., Mirandola, P., Carubbi, C., Giannini, S., Donati, D., Vitale, M.. - In: JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. - ISSN 1932-7005. - 8:6(2014), pp. 483-492. [10.1002/term.1551]
abstract:
Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) are currently used
alone or in combination for therapeutic applications especially for bone repair.
We tested whether MSCs can be isolated from bone marrow (BM) aspirate using a
commercially available kit commonly used to obtain PRP from peripheral blood
(PB). Results revealed that mononuclear cells and platelets from both PB and BM
could be efficiently isolated by obtaining a mononuclear and platelet rich
fraction (PB-MPRF and BM-MPRF, respectively). Starting with comparable volumes,
the number of platelets increased 1.5-fold in BM-MPRF compared to PB-MPRF. The
number of clonogenic cells in BM-MPRF samples was significantly higher than whole
BM samples as revealed by CFU-F assay (54.92 ± 8.55 CFU-F/1.5 x 10(5) nucleated
cells and 32.50 ± 12.43 CFU-F/1.5 x 10(5) nucleated cells, respectively). Cells
isolated from BM-MPRF after in vitro expansion fulfilled the definition of MSCs
by phenotypic criteria, and differentiated along osteogenic, adipogenic and
chondrogenic lineages following induction. Results showed that the kit isolated
MSCs and platelets from BM aspirate. Isolated MSCs were further expanded in a
laboratory and BM-MPRF was used clinically following BM withdrawal for rapid
intra-operative cell therapy for the treatment of bone defects.
alone or in combination for therapeutic applications especially for bone repair.
We tested whether MSCs can be isolated from bone marrow (BM) aspirate using a
commercially available kit commonly used to obtain PRP from peripheral blood
(PB). Results revealed that mononuclear cells and platelets from both PB and BM
could be efficiently isolated by obtaining a mononuclear and platelet rich
fraction (PB-MPRF and BM-MPRF, respectively). Starting with comparable volumes,
the number of platelets increased 1.5-fold in BM-MPRF compared to PB-MPRF. The
number of clonogenic cells in BM-MPRF samples was significantly higher than whole
BM samples as revealed by CFU-F assay (54.92 ± 8.55 CFU-F/1.5 x 10(5) nucleated
cells and 32.50 ± 12.43 CFU-F/1.5 x 10(5) nucleated cells, respectively). Cells
isolated from BM-MPRF after in vitro expansion fulfilled the definition of MSCs
by phenotypic criteria, and differentiated along osteogenic, adipogenic and
chondrogenic lineages following induction. Results showed that the kit isolated
MSCs and platelets from BM aspirate. Isolated MSCs were further expanded in a
laboratory and BM-MPRF was used clinically following BM withdrawal for rapid
intra-operative cell therapy for the treatment of bone defects.
Iris type:
1.1 Articolo in rivista
List of contributors:
Dozza, B.; Gobbi, Giuliana; Lucarelli, E.; Pierini, M.; Bella, C. D.; Frisoni, T.; Tazzari, P. L.; Ricci, F.; Mirandola, Prisco; Carubbi, Cecilia; Giannini, S.; Donati, D.; Vitale, Marco
Published in: